Final answer:
The statement is true; DPP-4 inhibitors extend the action of GLP-1, increasing insulin secretion, reducing glucagon levels, and slowing gastrointestinal emptying, thereby aiding in blood glucose control.
Step-by-step explanation:
The statement that DPP-4 inhibitors slow the breakdown of GLP-1 in the body, prolonging the effects of increased insulin secretion, decreased glucagon secretion, and slowed GI emptying is true. DPP-4 inhibitors are a class of medications used in the management of type 2 diabetes. They work by blocking the enzyme DPP-4, which normally breaks down incretin hormones such as GLP-1 (glucagon-like peptide-1). GLP-1 is crucial in regulating blood sugar levels by enhancing the secretion of insulin, which decreases blood glucose levels, and inhibiting glucagon, which would otherwise increase blood glucose levels. Additionally, GLP-1 slows gastric emptying, which contributes to satiety and further helps in blood glucose management. Therefore, by inhibiting DPP-4 and enhancing GLP-1's effects, blood sugar control is improved in diabetic patients.
- DPP-4 inhibitors block the enzyme DPP-4, slowing the breakdown of GLP-1.
- GLP-1 increases insulin and decreases glucagon secretion.
- DPP-4 inhibition prolongs insulin secretion, reduces glucagon levels, and slows GI emptying.